Atopic Dermatitis Treatment Market

Atopic Dermatitis Treatment Market: North America to Remain Dominant Regional Market Through 2027: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027

The global atopic dermatitis treatment market is poised to grow from close to US$ 7,225 Mn in 2017 to nearly US$ 24,000 Mn by 2027 end. This represents a CAGR of 12.8% over the forecast period. Revenue from the global atopic dermatitis treatment market is estimated to increase 4.1X during the period 2017 – 2027. This massive growth can be attributed to a rising prevalence of atopic dermatitis across the world as well as the introduction of innovative therapeutic options.

Industry consolidations leading to faster time-to-market in North America

Various companies are focussed on partnerships with other companies with products in advanced stages of development to enable quicker approval and marketing of their products. Allergan plc, a leading global pharmaceutical company, successfully completed purchasing all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focussed on innovative development programmes for dermatologic conditions in Oct 2016. The completion of the Vitae acquisition has added highly differentiated development compounds to Allergan’s medical dermatology pipeline. The parent company is able to leverage its clinical development expertise and regulatory knowledge to ensure a win-win situation through this partnership.

New classes of products launched in North America boosting the atopic dermatitis treatment market

Since December 2016, two new classes of drugs were launched targeting both mild-to-moderate atopic dermatitis as well as severe atopic dermatitis. The launch of new classes of drugs gives patients and healthcare professionals alternatives to other classes of drugs such as corticosteroids, which carry the risk of side effects and calcineurin inhibitors, which do not have patent protection anymore and are open to generic alternatives. The U.S. Food and Drug Administration (FDA) approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older in Dec 2016. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) inhibitor.

Side effects and high costs associated with biologic therapy may hamper the market in North America

Dupixent can cause side effects such as serious allergic reactions and eye problems, such as pink eye (conjunctivitis) and inflammation of the cornea (keratitis). The most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching. Additionally, the developers of the biologic therapy Dupixent have priced the drug at approximately US$ 37,000/year. It is uncertain if payers will cover the cost of treatment, considering other lower cost alternatives; which could hinder the adoption of the drug.

Global Atopic Dermatitis Treatment Market Attractiveness Analysis, by Region

North America dominated the global atopic dermatitis treatment market in terms of revenue in 2017, and the trend is projected to continue throughout the forecast period. North America is the most attractive regional market, with an attractiveness index of 3.4 over the forecast period. Revenue from the North America atopic dermatitis treatment market is anticipated to increase at a CAGR of 16.0% over 2017–2027, to reach a market valuation in excess of US$ 10,000 Mn by 2027. Western Europe is the second largest market in terms of revenue growth, anticipated to reach a market valuation of more than US$ 7800 Mn by the end of the forecast period – depicting a CAGR of 14.0%.

global atopic dermatitis treatment market

Increasing R&D focus on novel biologics will shape future corporate strategies

As the atopic dermatitis treatment market is currently highly generalised and there are only two key patent protected (U.S only) brands, no distinct trends exist. However, over the coming decade, the introduction of biologics, in particular interleukin inhibitors, will emerge as a key future strategy for this marketplace. Historically, Astellas and Novartis were the dominant market players in the atopic dermatitis treatment market for almost a decade, with the launch of the topical calcineurin inhibitor brands Protopic (tacrolimus) and Elidel (pimecrolimus), in the U.S in 2001. Although Astellas continues to maintain its strong standing in the current market, Novartis exited the space in April 2011, with the sale of Elidel’s rights to Meda. To some extent, Novartis continues to have a presence in this market, as some dermatologists opt for its brand edversions of cyclosporine, Sand immune or Neoral, for their atopic dermatitis patients requiring a systemic immune modulator.

Future Market Insights in its latest report titled ‘Atopic Dermatitis Treatment Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027’ gives a comprehensive assessment of the global atopic dermatitis treatment market. The report starts with an executive summary that gives a concise overview of the atopic dermatitis treatment market along with key market numbers and most important segments and regions in this market. Also, important trends, factors and opportunities governing the atopic dermatitis treatment market are given so that the report audiences get an overview of the market dynamics operating in this market. In addition, in the executive summary, global atopic dermatitis treatment market revenue share by drug type, by mode of administration, by distribution channel and by region for the years 2016 and 2027 are given. In another part of the executive summary, there is also a concise yet informative Future Market Insights analysis on the overall market approach of the leading players operating in the global atopic dermatitis treatment market and information is also given on the target segments and the target countries that are most lucrative in this market. The differentiating strategies of the leading market players is also given in this sub section of the executive summary. At the end of the executive summary, there is a diagrammatic representation of the various stages of the global atopic dermatitis treatment market in the form of the introduction phase, growth phase, maturity phase and decline phase. After the executive summary, there is a section on the market introduction which gives a detailed market taxonomy of the global atopic dermatitis treatment market.

Market Taxonomy

By Drug Type

By Mode of Administration

By Distribution Channel

By Region

  • Corticosteroids

  • Calcineurin Inhibitors

  • Immunosuppressants

  • Biologic Therapy

  • PDE-4 Inhibitor

  • Antibiotics

  • Antihistamines

  • Emollients

  • Topical

  • Oral

  • Injectable

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Drug Stores

  • Mail Order Pharmacies

  • Dermatology Clinics

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific excluding Japan

  • Middle East and Africa

  • Japan

A section of the report is devoted to the definition of atopic dermatitis and its various causes and symptoms. In another section of the report, the preferred modes of treatment for atopic dermatitis are given, by the degree of severity. In the section that follows, the definitions of the drugs used for the treatment of atopic dermatitis are given. Also, global epidemiology of atopic dermatitis is stated. In another part of the report, the global atopic dermatitis treatment market size is compared with its parent market size, comprising the global dermatology drugs and devices market. Also, key regulations and guidelines for the treatment of atopic dermatitis are mentioned in this section. The subsequent sections of the report contain information about the regional market analysis (2012-2016) and forecast (2017-2027) of the atopic dermatitis treatment market as per the regions given in the market taxonomy. These sections contain a detailed subsection on the market dynamics of the atopic dermatitis treatment market.

There is an exhaustive explanation about the drivers, restraints and trends applicable in the atopic dermatitis treatment market pertaining to the regions assessed. This is an important subsection of the report as it contains a detailed explanation about the factors that encourage the growth of this market as well as the factors that hamper the growth of this market. Besides this, weightage of impact of the forecast factors is also highlighted. The regional subsections of this report contain important market information in the form of atopic dermatitis treatment market size (US$ Mn) forecast by country, by drug type, by mode of administration and by distribution channel. Market attractiveness index for each of the segments as presented in the market taxonomy is also given.

An entire section of the report is devoted to the competition landscape of the global atopic dermatitis treatment market. This competition landscape gives a dashboard view of the key companies operating in the global atopic dermatitis treatment market along with their important information and broad strategy adopted to stay as leaders in the global atopic dermatitis treatment market. Each of the leading companies is also profiled individually and important information about the company such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis is presented. A SWOT analysis of each leading market player is also presented in this section. This competition landscape is the most important section of the report as it imparts a deep understanding of the leading companies operating in the global atopic dermatitis treatment market.

Research Methodology

Overall market size has been analysed through historical data, primary responses, and public domain data. Revenue of companies in the atopic dermatitis treatment market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to forecast the market size over the forecast period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinised using advanced tools to garner quantitative and qualitative insights into the global atopic dermatitis treatment market.